Overview

Phase 2 Study With SNF472 in Calciphylaxis Patients

Status:
Completed
Trial end date:
2017-11-15
Target enrollment:
Participant gender:
Summary
To evaluate the effect of SNF472 on top of standard of care on promoting wound healing and other parameters of therapeutic response in haemodialysis patients with calciphylaxis (calcific uraemic arteriolopathy, CUA).
Phase:
Phase 2
Details
Lead Sponsor:
Laboratoris Sanifit
Sanifit Therapeutics S. A.